| Ident. | Authors (with country if any) | Title |
|---|
| 000304 |
Virginie Czernecki [France] ; Michael Schüpbach [France, Suisse] ; Sadek Yaici [France] ; Richard Lévy [France] ; Eric Bardinet [France] ; Jérôme Yelnik [France] ; Bruno Dubois [France] ; Yves Agid [France] | Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom |
| 000383 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors |
| 000535 |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 000560 |
Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study |
| 000561 |
Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study |
| 000654 |
Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse] | Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease |
| 000672 |
J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse] | Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease |
